Biotechnology

From Frenzy Capital
Jump to navigation Jump to search

Symbol Name Rank Change Headline Date
OTIC Otonomy Inc 42.38 120.448 U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.01% By Investing.com - Investing.com 11/29/2022, 16:25:00
OTIC Otonomy Inc 42.38 120.448 Why Shares Of Chinese Companies Are Trading Higher? Here Are 45 Stocks Moving In Tuesday’s Mid-Day Sessio - Benzinga 11/29/2022, 11:47:48
OTIC Otonomy Inc 42.38 120.448 Where Does Otonomy Inc (OTIC) Stock Fall in the Biotechnology Field After It Is Up 137.50% This Week? - InvestorsObserver 11/29/2022, 11:39:10
OTIC Otonomy Inc 42.38 120.448 Thinking about buying stock in Nike, Otonomy, Wynn Resorts, Weibo, or Block? - Marketscreener.com 11/29/2022, 11:10:03
OTIC Otonomy Inc 42.38 120.448 Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation - Marketscreener.com 11/29/2022, 08:01:46
CRBP Corbus Pharmaceuticals Holdings Inc 10.06 29.4904 Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch 11/28/2022, 16:50:00
CRBP Corbus Pharmaceuticals Holdings Inc 10.06 29.4904 Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket - Alset (N - Benzinga 11/21/2022, 07:45:08
CRBP Corbus Pharmaceuticals Holdings Inc 10.06 29.4904 Corbus Pharmaceuticals Holdings Inc. stock falls Thursday, underperforms market - MarketWatch 11/17/2022, 03:00:00
CRBP Corbus Pharmaceuticals Holdings Inc 10.06 29.4904 Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday’s Mid- - Benzinga 11/15/2022, 03:00:00
CRBP Corbus Pharmaceuticals Holdings Inc 10.06 29.4904 Why PlayAGS Shares Are Trading Lower By Over 15%; Here Are 33 Stocks Moving Premarket - BIMI Intl Medical - Benzinga 11/15/2022, 03:00:00
AMGN AMGEN Inc. 4.04 -0.789 Drugmaker Astellas Has Claims For DOJ Settlement Coverage - Law360 11/29/2022, 18:38:00
AMGN AMGEN Inc. 4.04 -0.789 Apple’s Cook Goes to Washington to Meet With Top GOP Lawmakers - Yahoo Finance 11/29/2022, 18:27:47
AMGN AMGEN Inc. 4.04 -0.789 Horizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi - Reuters 11/29/2022, 18:12:00
AMGN AMGEN Inc. 4.04 -0.789 3 rumors pushing around stocks today By Investing.com - Investing.com India 11/29/2022, 17:53:15
AMGN AMGEN Inc. 4.04 -0.789 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
XFOR X4 Pharmaceuticals Inc 3.68 -11.9318 X4 PHARMACEUTICALS, INC : Regulation FD Disclosure, Other Events (form 8-K) - Marketscreener.com 11/29/2022, 16:08:08
XFOR X4 Pharmaceuticals Inc 3.68 -11.9318 Layoff Tracker 2022: Spectrum, Tricida, Pear Therapeutics and More Cull Staff BioSpace - BioSpace 11/29/2022, 11:02:44
XFOR X4 Pharmaceuticals Inc 3.68 -11.9318 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
XFOR X4 Pharmaceuticals Inc 3.68 -11.9318 Layoff Tracker: Curis, Adaptimmune plus 90+ more - FierceBiotech 11/28/2022, 15:37:30
XFOR X4 Pharmaceuticals Inc 3.68 -11.9318 Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline - FierceBiotech 11/28/2022, 11:12:06
MRTX Mirati Therapeutics Inc 3.62 -5.404 Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations - Yahoo Finance 11/29/2022, 08:00:00
MRTX Mirati Therapeutics Inc 3.62 -5.404 Charles M. Baum Sells 69256 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) Stock - MarketBeat 11/28/2022, 21:20:01
MRTX Mirati Therapeutics Inc 3.62 -5.404 Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO - Marketscreener.com 11/28/2022, 08:01:11
MRTX Mirati Therapeutics Inc 3.62 -5.404 6 biggest deal reports this week: Manchester United open to selling the club By Investing.com - Investing.com 11/26/2022, 17:02:00
MRTX Mirati Therapeutics Inc 3.62 -5.404 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - Yahoo Finance 11/23/2022, 10:30:00
BIIB Biogen Inc 3.35 0.7194 A new Alzheimer's treatment may help some patients, though researchers say more safety data is needed - MarketWatch 11/29/2022, 20:23:00
BIIB Biogen Inc 3.35 0.7194 New data shows Alzheimer's drug can slow cognitive decline - ABC News 11/29/2022, 20:07:25
BIIB Biogen Inc 3.35 0.7194 Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus - Marketscreener.com 11/29/2022, 19:54:49
BIIB Biogen Inc 3.35 0.7194 Alzheimer's Drug Results From Eisai (4523 JP), Biogen (BIIB) Spark Debate - Bloomberg 11/29/2022, 19:50:00
BIIB Biogen Inc 3.35 0.7194 EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE - PR Newswire 11/29/2022, 19:50:00
FGEN FibroGen Inc 3.35 1.4235 Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors - PR Newswire 11/29/2022, 08:00:00
FGEN FibroGen Inc 3.35 1.4235 Global Aesthetic Injectables Market Key Players, Growth Opportunities, Future Challenges, Application, CAGR, Forecast by 2029 - Digital Journal 11/29/2022, 07:51:29
FGEN FibroGen Inc 3.35 1.4235 Myelodysplastic Syndrome (MDS) Treatment Market See Incredible Growth 2022-2028 Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd. - Digital Journal 11/29/2022, 04:30:56
FGEN FibroGen Inc 3.35 1.4235 Where Does FibroGen Inc (FGEN) Stock Fall in the Biotechnology Field After It Has Fallen -4.54% This Week? - InvestorsObserver 11/28/2022, 14:25:35
FGEN FibroGen Inc 3.35 1.4235 Duchenne Muscular Dystrophy Market to Reach $2.1 Billion, Globally, by 2031 at 4.7% CAGR: Allied Market Research - PR Newswire 11/28/2022, 07:10:00
SRNE Sorrento Therapeutics Inc 1.94 -0.813 Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir - GlobeNewswire 11/29/2022, 14:06:27
SRNE Sorrento Therapeutics Inc 1.94 -0.813 Knee Osteoarthritis Pipeline Therapies Assessment, 2022 Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Players - Digital Journal 11/29/2022, 13:41:37
SRNE Sorrento Therapeutics Inc 1.94 -0.813 CAR T Cell Therapy Market See Incredible Growth 2022-2028 Novartis AG, McKinsey & Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Amgen Inc. - Digital Journal 11/29/2022, 04:30:56
SRNE Sorrento Therapeutics Inc 1.94 -0.813 Sorrento Therapeutics Inc (SRNE) Stock Has Fallen -12.96% This Week: Buy, Hold, or Sell? - InvestorsObserver 11/17/2022, 15:08:09
SRNE Sorrento Therapeutics Inc 1.94 -0.813 Sorrento Therapeutics Inc (SRNE) Up 9.29% in Premarket Trading - InvestorsObserver 11/14/2022, 06:54:46
VTGN VistaGen Therapeutics Inc 1.72 27.3469 Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer - Financial Post 11/23/2022, 11:42:30
VTGN VistaGen Therapeutics Inc 1.72 27.3469 VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/23/2022, 06:04:08
VTGN VistaGen Therapeutics Inc 1.72 27.3469 VISTAGEN THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/22/2022, 06:04:12
VTGN VistaGen Therapeutics Inc 1.72 27.3469 Vistagen Therapeutics Inc (VTGN) Stock Has Risen 15.38% This Week: Buy, Hold, or Sell? - InvestorsObserver 11/17/2022, 12:53:10
VTGN VistaGen Therapeutics Inc 1.72 27.3469 VistaGen Therapeutics, Inc. (VTGN) Q2 2023 Earnings Call Transcript - Seeking Alpha 11/10/2022, 03:00:00
VBLT Vascular Biogenics Ltd 1.69 4.5752 13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance 11/29/2022, 17:43:35
VBLT Vascular Biogenics Ltd 1.69 4.5752 What is the Market's View on Vascular Biogenics Ltd (VBLT) Stock's Price and Volume Trends Tuesday? - InvestorsObserver 11/29/2022, 11:52:29
VBLT Vascular Biogenics Ltd 1.69 4.5752 Can Vascular Biogenics Ltd. (VBLT) Remain Competitive? - The News Heater 11/29/2022, 11:50:03
VBLT Vascular Biogenics Ltd 1.69 4.5752 Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday - Autodesk (NASDAQ - Benzinga 11/25/2022, 04:52:36
VBLT Vascular Biogenics Ltd 1.69 4.5752 Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday’s Mid-Day S - Benzinga 11/23/2022, 13:27:38
GERN Geron Corp. 1.55 3.9301 Myelodysplastic Syndrome (MDS) Treatment Market See Incredible Growth 2022-2028 Celgene Corporation, Otsuka Pharmaceutical Co., Ltd. Teva Pharmaceutical Industries Ltd. - Digital Journal 11/29/2022, 04:30:56
GERN Geron Corp. 1.55 3.9301 Hygienic Night Pants Market Size 2022, Top Countries Segmented by Applications and Geography Trends – Skegness Siren - Skegness Siren 11/28/2022, 00:31:29
GERN Geron Corp. 1.55 3.9301 [2022-2030 Human Embryonic Stem Cells (Hesc) Market will Witness Substantial Growth With in-detailed Competit - openPR] 11/23/2022, 08:02:00
GERN Geron Corp. 1.55 3.9301 No JuJu Smith-Schuster or Mecole Hardman for Chiefs? Worked out OK as others stepped up - Kansas City Star 11/23/2022, 08:00:00
GERN Geron Corp. 1.55 3.9301 Should You Add Geron Corporation (GERN) Stock to Your Portfolio Friday? - InvestorsObserver 11/18/2022, 12:52:03
FREQ Frequency Therapeutics Inc 1.52 4.7619 New study provides evidence for three-year interval for multi-target stool DNA screening for those at average risk of colon cancer - Science Daily 11/29/2022, 19:52:17
FREQ Frequency Therapeutics Inc 1.52 4.7619 Computer Vision and AI Solutions Pioneer Spacee Adds Thiel Capital Managing Director, Former PayPal SVP to Advisory Board - dallasinnovates.com 11/29/2022, 19:00:00
FREQ Frequency Therapeutics Inc 1.52 4.7619 Funding Roundup: Akeyless, Boost Security, CG Oncology, FogPharma, Kyte, Ordergroove, PayZen, Swell Energy, Vizit, WEKA, WorkJam, And Others - Pulse 2.0 11/29/2022, 12:57:00
FREQ Frequency Therapeutics Inc 1.52 4.7619 Nestlé reconsiders peanut allergy program two years after $2.6B buyout - Endpoints News 11/29/2022, 12:48:00
FREQ Frequency Therapeutics Inc 1.52 4.7619 SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Frequency Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors - Longview News-Journal 11/29/2022, 11:05:00
PBYI Puma Biotechnology Inc 1.52 2.9478 Is Puma Biotechnology Inc (PBYI) Stock Over or Undervalued? - InvestorsObserver 11/28/2022, 11:56:19
PBYI Puma Biotechnology Inc 1.52 2.9478 Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday By Benzinga - Investing.com UK 11/28/2022, 06:10:00
PBYI Puma Biotechnology Inc 1.52 2.9478 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product Type (Monotherapy, Combination Therapy), Application (Breast Cancer, Gastric Cancer, Ovarian Cancer, Others), and Geography – Global Trends & Forecasts to 2019-202 - Skegness Siren 11/26/2022, 01:35:29
PBYI Puma Biotechnology Inc 1.52 2.9478 Healthcare Stocks on the Move Friday: EUDA, PKBO, CGTX, NUTX, CHEK, NMTC, XGN, PBYI - InvestorsObserver 11/25/2022, 14:20:25
PBYI Puma Biotechnology Inc 1.52 2.9478 Puma Biotechnology Inc (PBYI) Stock: Do Analysts Think You Should Sell? - InvestorsObserver 11/23/2022, 15:38:46
RDHL Redhill Biopharma - ADR 1.12 -6.9333 $RDHL Redhill Biopharma Announces Q3/22 Results And Operational Highlights - CML News 11/29/2022, 08:25:00
RDHL Redhill Biopharma - ADR 1.12 -6.9333 Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - Yahoo Finance 11/08/2022, 03:00:00
RDHL Redhill Biopharma - ADR 1.12 -6.9333 RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha 12/30/2021, 03:00:00
RDHL Redhill Biopharma - ADR 1.12 -6.9333 RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha 09/04/2018, 03:00:00
RDHL Redhill Biopharma - ADR 1.12 -6.9333 Redhill Share Price Today %EXCHANGE_SYMBOL% RDHL Stock - Investing.com India 05/13/2017, 15:41:25
QURE uniQure N.V. 1.1 -4.0996 Other news to note for Nov. 29, 2022 - BioWorld Online 11/29/2022, 17:41:50
QURE uniQure N.V. 1.1 -4.0996 UniQure NV Says Preclinical Data Support AMT-260 Gene Therapy's Safety, Tolerability - Marketscreener.com 11/29/2022, 15:33:03
QURE uniQure N.V. 1.1 -4.0996 BMS Terminates 2015 Gene Therapy Pact with uniQure - BioSpace 11/29/2022, 15:21:32
QURE uniQure N.V. 1.1 -4.0996 Where Will Uniqure NV (QURE) Stock Go Next After It Has Risen 21.37% in a Week? - InvestorsObserver 11/29/2022, 14:51:45
QURE uniQure N.V. 1.1 -4.0996 uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event - Yahoo Finance 11/29/2022, 11:00:00
IMVT Immunovant Inc 1.08 -5.3731 Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat 11/29/2022, 03:15:33
IMVT Immunovant Inc 1.08 -5.3731 Are Medical Stocks Lagging BioVie (BIVI) This Year? - Nasdaq 11/25/2022, 09:40:00
IMVT Immunovant Inc 1.08 -5.3731 Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How - Zacks Investment Research 11/17/2022, 03:00:00
IMVT Immunovant Inc 1.08 -5.3731 Is it Time to Dump Immunovant Inc (IMVT) Stock After it Has Gained 4.43% in a Week? - InvestorsObserver 11/08/2022, 12:40:23
IMVT Immunovant Inc 1.08 -5.3731 Wells Fargo Adjusts Price Target on Immunovant to $10 From $7, Maintains Equal-Weight Rating - Marketscreener.com 11/08/2022, 12:01:02
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.84 -3.0914 Lysosomal Storage Diseases Market 2022 Growth Factors, Opportunities, Ongoing Trends and Key Players 2032 - Digital Journal 11/28/2022, 21:27:58
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.84 -3.0914 BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A - Investor Relations : BioMarin 11/23/2022, 08:34:16
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.84 -3.0914 GSK, J&J, and AZ top 2022 drug access index - FiercePharma 11/16/2022, 03:00:00
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.84 -3.0914 PTC Therapeutics: PKU Trial News Likely To Shore Up Share Price - Seeking Alpha 11/15/2022, 03:00:00
BMRN Biomarin Pharmaceutical Inc. - Registered Shares 0.84 -3.0914 Emergent lowers 2022 revenue guidance across the board - FiercePharma 11/11/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.81 -9.1286 Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer Prostate Cancer and Prostatic Diseases - Nature.com 11/29/2022, 16:47:38
ABCM Abcam - ADR (Sponsored) 0.81 -9.1286 Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities - Science 11/09/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.81 -9.1286 The 7 Best Stocks Under $15 to Buy Now - InvestorPlace 11/08/2022, 03:00:00
ABCM Abcam - ADR (Sponsored) 0.81 -9.1286 AIM Delisting – Abcam plc - Abcam plc 10/17/2022, 02:28:49
ABCM Abcam - ADR (Sponsored) 0.81 -9.1286 Interim results for the period ended 30 June 2022 – Abcam plc - Abcam plc 06/30/2022, 03:00:00
VXRT Vaxart Inc 0.61 0 Premarket Mover: Vaxart Inc (VXRT) Up 3.08% - InvestorsObserver 11/25/2022, 08:50:39
VXRT Vaxart Inc 0.61 0 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - PR Newswire 11/23/2022, 10:30:00
VXRT Vaxart Inc 0.61 0 Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 - Marketscreener.com 11/22/2022, 08:36:44
VXRT Vaxart Inc 0.61 0 Vaxart, Inc. (VXRT) Stock Price Today, Quote & News - Seeking Alpha 11/17/2022, 03:00:00
VXRT Vaxart Inc 0.61 0 Q4 2022 Earnings Forecast for Vaxart, Inc. Issued By Brookline Capital Management (NASDAQ:VXRT) - MarketBeat 11/16/2022, 03:00:00
IONS Ionis Pharmaceuticals Inc 0.59 -3.8681 Relative Strength Alert For Ionis Pharmaceuticals - Nasdaq 11/29/2022, 16:29:00
IONS Ionis Pharmaceuticals Inc 0.59 -3.8681 Is Ionis Pharmaceuticals Inc (IONS) a Good Buy in the Biotechnology Industry? - InvestorsObserver 11/29/2022, 12:39:33
IONS Ionis Pharmaceuticals Inc 0.59 -3.8681 Transcript : Ionis Pharmaceuticals, Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM - Marketscreener.com 11/29/2022, 10:00:00
IONS Ionis Pharmaceuticals Inc 0.59 -3.8681 U.S. Transthyretin Amyloidosis Treatment Market Size will Grow Profitably in upcoming Estimation year 2028 Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc. - Digital Journal 11/29/2022, 04:30:56
IONS Ionis Pharmaceuticals Inc 0.59 -3.8681 Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain DelveInsight - Yahoo Finance 11/28/2022, 13:00:00
SGEN Seagen Inc 0.57 -3.1513 Horizon Therapeutics in Separate Sale Talks With Amgen, Sanofi, J&J - Bloomberg 11/29/2022, 18:57:50
SGEN Seagen Inc 0.57 -3.1513 Steven Cohen Loads Up on Workday, Dumps Coca-Cola - GuruFocus.com 11/29/2022, 18:27:45
SGEN Seagen Inc 0.57 -3.1513 Roche Withdraws Tecentriq's Frontline Bladder Cancer Indication, Ceding Market To Keytruda - Scrip 11/29/2022, 17:25:16
SGEN Seagen Inc 0.57 -3.1513 Incyte Corp. stock falls Tuesday, still outperforms market - MarketWatch 11/29/2022, 17:09:00
SGEN Seagen Inc 0.57 -3.1513 The Global Duodenoscopes Market is Predicted to Surge at a CAGR of 5.2% by 2027, Assesses DelveInsight - GlobeNewswire 11/29/2022, 13:00:00
ALLO Allogene Therapeutics Inc 0.52 -8.3821 Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform - GlobeNewswire 11/29/2022, 15:30:12
ALLO Allogene Therapeutics Inc 0.52 -8.3821 Nestlé reconsiders peanut allergy program two years after $2.6B buyout - Endpoints News 11/29/2022, 12:48:00
ALLO Allogene Therapeutics Inc 0.52 -8.3821 Boehringer Ingelheim buys CD38 drug; Merck bets on machine learning in antibody design - Endpoints News 11/29/2022, 10:57:00
ALLO Allogene Therapeutics Inc 0.52 -8.3821 Viatris withdraws accelerated approval for topical antimicrobial 24 years later - Endpoints News 11/29/2022, 10:53:00
ALLO Allogene Therapeutics Inc 0.52 -8.3821 Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca - Endpoints News 11/29/2022, 08:00:00
ATHA Athira Pharma Inc 0.52 1.0563 Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference - GlobeNewswire 11/29/2022, 11:00:00
ATHA Athira Pharma Inc 0.52 1.0563 Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND - Marketscreener.com 11/28/2022, 07:01:02
ATHA Athira Pharma Inc 0.52 1.0563 Athira Pharma, Inc. (NASDAQ:ATHA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat 11/20/2022, 01:10:55
ATHA Athira Pharma Inc 0.52 1.0563 ATHIRA PHARMA, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/18/2022, 16:09:10
ATHA Athira Pharma Inc 0.52 1.0563 Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying - Athira - Benzinga 11/18/2022, 03:00:00
IBIO iBio Inc 0.35 2.0134 iBio Inc. stock rises Tuesday, outperforms market - MarketWatch 11/29/2022, 17:07:00
IBIO iBio Inc 0.35 2.0134 Plant-based Expression Systems Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance 11/29/2022, 04:15:00
IBIO iBio Inc 0.35 2.0134 Plant Based Biologics Market Projected to Grow at a CAGR of 3.4 % throughout 2022 – 2030 - Digital Journal 11/28/2022, 03:41:55
IBIO iBio Inc 0.35 2.0134 Plant-Based Vaccines Market Future Developments, Business Insights, End Users, Application And Forecast To 2028 Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, - Digital Journal 11/23/2022, 07:06:05
IBIO iBio Inc 0.35 2.0134 iBio Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/22/2022, 17:00:00
VIR Vir Biotechnology Inc 0.32 -0.9276 VAST Data fifth fastest growing US tech company – Blocks and Files - Blocks and Files 11/28/2022, 05:47:00
VIR Vir Biotechnology Inc 0.32 -0.9276 Analysts Have Given Vir Biotechnology, Inc. (NASDAQ:VIR) an Average Rating of "Hold" - Best Stocks 11/26/2022, 16:38:36
VIR Vir Biotechnology Inc 0.32 -0.9276 Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Hold" by Analysts - MarketBeat 11/26/2022, 02:02:49
VIR Vir Biotechnology Inc 0.32 -0.9276 Seasonal Influenza Market to Proliferate at a CAGR of 6.1% During the Forecast Period (2022-2032), Assesses DelveInsight - PR Newswire 11/23/2022, 10:30:00
VIR Vir Biotechnology Inc 0.32 -0.9276 Tackle.io among fastest-growing tech companies in Deloitte's 2022 list - The Business Journals 11/23/2022, 09:16:00
GILD Gilead Sciences, Inc. 0.32 0.6337 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
GILD Gilead Sciences, Inc. 0.32 0.6337 Gilead Sciences Inc. stock rises Tuesday, outperforms market - MarketWatch 11/29/2022, 17:03:00
GILD Gilead Sciences, Inc. 0.32 0.6337 Transcript : Gilead Sciences, Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 01:00 PM - Marketscreener.com 11/29/2022, 13:00:00
GILD Gilead Sciences, Inc. 0.32 0.6337 AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy - Scrip 11/29/2022, 12:37:43
GILD Gilead Sciences, Inc. 0.32 0.6337 After falling flat weeks ago, BMS is knocking on the Supreme Court's door once again - FiercePharma 11/29/2022, 10:56:27
CRSP CRISPR Therapeutics AG 0.32 -2.5122 Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D - FierceBiotech 11/29/2022, 11:14:15
CRSP CRISPR Therapeutics AG 0.32 -2.5122 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
CRSP CRISPR Therapeutics AG 0.32 -2.5122 Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal - FierceBiotech 11/29/2022, 08:24:27
CRSP CRISPR Therapeutics AG 0.32 -2.5122 Propulsion of Thalassemia Pipeline as Novel and Extensive 25+ Therapies Likely to Enter in the Treatment Domain DelveInsight - Yahoo Finance 11/28/2022, 13:00:00
CRSP CRISPR Therapeutics AG 0.32 -2.5122 Want To Live Longer (and Richer)? Invest in Genomics - DataDrivenInvestor 11/28/2022, 06:18:44
PTN Palatin Technologies Inc. 0.32 -0.2591 Where Does Palatin Technologies, Inc. (PTN) Stock Fall in the Biotechnology Field After It Is Lower By -2.76% This Week? - InvestorsObserver 11/25/2022, 13:36:57
PTN Palatin Technologies Inc. 0.32 -0.2591 Palatin Technologies, Inc. (PTN) Stock Price Today, Quote & News - Seeking Alpha 11/21/2022, 03:00:00
PTN Palatin Technologies Inc. 0.32 -0.2591 PALATIN TECHNOLOGIES INC : Results of Operations and Financial Condition (form 8-K) - Marketscreener.com 11/14/2022, 08:04:17
PTN Palatin Technologies Inc. 0.32 -0.2591 North American Morning Briefing : Fed's Waller -2- - Marketscreener.com 11/14/2022, 05:31:02
PTN Palatin Technologies Inc. 0.32 -0.2591 Palatin Technologies, Inc. (PTN) Q1 2023 Earnings Call Transcript - Seeking Alpha 11/14/2022, 03:00:00
PSTX Poseida Therapeutics Inc 0.3 9.0686 Is Poseida Therapeutics Inc (PSTX) a Bad Choice in Biotechnology Tuesday? - InvestorsObserver 11/29/2022, 11:57:26
PSTX Poseida Therapeutics Inc 0.3 9.0686 Human Gene Therapy Market by Product Type (Non-viral Vectors, Viral Vectors), Application (Neurological Diseases, Cancer, DMD (Duchenne Muscular Dystrophy), Hepatological Diseases, Others), and Geography – Global Trends & Forecasts to 2019- - Skegness Siren 11/27/2022, 02:26:08
PSTX Poseida Therapeutics Inc 0.3 9.0686 AAV Vectors in Gene Therapy - Pipeline Insight, 2022 - ResearchAndMarkets.com - Business Wire 11/22/2022, 11:59:00
PSTX Poseida Therapeutics Inc 0.3 9.0686 Should You Add Poseida Therapeutics Inc (PSTX) Stock to Your Portfolio Monday? - InvestorsObserver 11/21/2022, 12:59:31
PSTX Poseida Therapeutics Inc 0.3 9.0686 Poseida Therapeutics: Early Stage CAR-T Developer Seeing Big Pharma Interest (NASDAQ:PSTX) - Seeking Alpha 11/18/2022, 03:00:00
CCCC C4 Therapeutics Inc 0.3 0.6289 Is C4 Therapeutics Inc (CCCC) a Stock to Watch After Losing -16.53% This Week? - InvestorsObserver 11/29/2022, 14:52:39
CCCC C4 Therapeutics Inc 0.3 0.6289 Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday’s Mid-Day Session - - Benzinga 11/25/2022, 12:01:57
CCCC C4 Therapeutics Inc 0.3 0.6289 C4 Therapeutics Inc (CCCC) has fallen -17.08% in a Week, Should You Sell? - InvestorsObserver 11/25/2022, 11:42:58
CCCC C4 Therapeutics Inc 0.3 0.6289 US Stocks Mixed On Black Friday; Dow Rises Over 100 Points - Check-Cap (NASDAQ:CHEK), C4 Therapeutics (NA - Benzinga 11/25/2022, 10:06:54
CCCC C4 Therapeutics Inc 0.3 0.6289 Captor Therapeutics Reports Q3 2022 Results and Provides Business Update - GlobeNewswire 11/25/2022, 08:00:00
NKTR Nektar Therapeutics 0.3 -5.8065 Mirum blames enrollment woes for halting phase 2 trial for pregnancy liver disorder - FierceBiotech 11/29/2022, 09:56:03
NKTR Nektar Therapeutics 0.3 -5.8065 AstraZeneca inks $200M solid tumor TCR cell therapy buyout - FierceBiotech 11/29/2022, 07:01:16
NKTR Nektar Therapeutics 0.3 -5.8065 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
NKTR Nektar Therapeutics 0.3 -5.8065 Dual drug nanoparticle could curb chemo resistance - FierceBiotech 11/28/2022, 15:37:30
NKTR Nektar Therapeutics 0.3 -5.8065 Master and PhD programs in pharmaceutical sciences underway Binghamton News - Binghamton 11/28/2022, 14:49:56
CMRX Chimerix Inc 0.29 -1.8349 Glioblastoma Multiforme Market to Grow Significantly at a CAGR of 13.1% During the Forecast Period (2022-2032) DelveInsight - PR Newswire 11/28/2022, 10:30:00
CMRX Chimerix Inc 0.29 -1.8349 Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28 - openPR 11/28/2022, 01:43:00
CMRX Chimerix Inc 0.29 -1.8349 Global Antiviral Drugs Market Report 2022: A New Approach to Developing Antiviral Drugs Could Slow Future Viral Outbreaks and Save Lives - ResearchAndMarkets.com - Business Wire 11/24/2022, 06:11:00
CMRX Chimerix Inc 0.29 -1.8349 Is Chimerix Inc (CMRX) a Stock to Watch After Gaining 4.09% This Week? - InvestorsObserver 11/23/2022, 12:08:41
CMRX Chimerix Inc 0.29 -1.8349 Monkeypox Treatment Market Future Business Opportunities 2022-2028 SIGA Technologies Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA. - Digital Journal 11/21/2022, 08:00:33
RGEN Repligen Corp. 0.29 -2.4179 Repligen Co. (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat 11/29/2022, 03:15:33
RGEN Repligen Corp. 0.29 -2.4179 Prepacked Chromatography Columns Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2022–2028 Hawach Scientific Co., Ltd., Purolite, BioServUK Ltd., Astrea Bioseparations Ltd., - Digital Journal 11/29/2022, 02:54:01
RGEN Repligen Corp. 0.29 -2.4179 Global Single Use Consumables Market Report 2022 to 2027: Lower Operational Cost and Increased Productivity is Driving Growth - PR Newswire 11/28/2022, 14:45:00
RGEN Repligen Corp. 0.29 -2.4179 The Worldwide Single-use Filtration Assemblies Industry is Expected to Reach $6.44 Billion by 2027 - Rapid Implementation and Low Risk of Cross-Contamination is Driving Growth - ResearchAndMarkets.com - Business Wire 11/28/2022, 07:15:00
RGEN Repligen Corp. 0.29 -2.4179 Single-Use Assemblies Market 2022-2028: Emerging Trends, Mergers and Acquisitions, Expansion Plans and Forecasts Research – Merck Millipore, Avantor, Thermo Fisher Scientific – Skegness Siren - Skegness Siren 11/28/2022, 00:31:29
EIGR Eiger BioPharmaceuticals Inc 0.29 -0.6865 2022-11-29 NDAQ:EIGR Press Release Eiger BioPharmaceuticals Inc. - Stockhouse 11/29/2022, 16:02:30
EIGR Eiger BioPharmaceuticals Inc 0.29 -0.6865 EIGR ALERT: The Klein Law Firm - GuruFocus.com 11/29/2022, 06:01:04
EIGR Eiger BioPharmaceuticals Inc 0.29 -0.6865 ROSEN, A TOP RANKED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors With Losses to Secure Couns - Benzinga 11/28/2022, 17:28:00
EIGR Eiger BioPharmaceuticals Inc 0.29 -0.6865 Eiger Biopharmaceuticals, Inc. (EIGR) Equity Notice: Contact Robbins LLP if You Incurred Significant Damages From Your Investment in Eiger Biopharmaceuticals, Inc. - GlobeNewswire 11/28/2022, 17:00:45
EIGR Eiger BioPharmaceuticals Inc 0.29 -0.6865 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ... - The Bakersfield Californian 11/28/2022, 14:21:17
ACOR Acorda Therapeutics Inc 0.29 -3.0851 Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Down 45.8% in November - Armenian Reporter 11/29/2022, 02:26:33
ACOR Acorda Therapeutics Inc 0.29 -3.0851 Global Ataxia Market Size To Grow USD 69,889.4 Million By - GlobeNewswire 11/28/2022, 13:30:00
ACOR Acorda Therapeutics Inc 0.29 -3.0851 Erythromelalgia Treatment Market by Product Type (Drugs, Therapy), Application (Primary Erythromelalgia, Secondary Erythromelalgia), and Geography – Global Trends & Forecasts to 2019-2029 – Skegness Siren - Skegness Siren 11/26/2022, 02:18:45
ACOR Acorda Therapeutics Inc 0.29 -3.0851 BMY: 3 Stocks to Buy This Month if You Haven't Already - StockNews.com 11/23/2022, 15:08:30
ACOR Acorda Therapeutics Inc 0.29 -3.0851 RoadMap Technologies Achieves HITRUST Risk-based, 2-year Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements - Yahoo Finance 11/17/2022, 03:00:00
RIGL Rigel Pharmaceuticals 0.29 -0.4359 RIGEL PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com 11/29/2022, 16:08:08
RIGL Rigel Pharmaceuticals 0.29 -0.4359 Layoff Tracker 2022: Spectrum, Tricida, Pear Therapeutics and More Cull Staff BioSpace - BioSpace 11/29/2022, 11:02:44
RIGL Rigel Pharmaceuticals 0.29 -0.4359 Novel activators of AMPK show efficacy in models of type 2 diabetes - BioWorld Online 11/16/2022, 03:00:00
RIGL Rigel Pharmaceuticals 0.29 -0.4359 The Global Tyrosine Kinase Inhibitors Market is expected to grow by $19.07 bn during 2022-2026, accelerating at a CAGR of 7.73% during the forecast period - Yahoo Finance 11/16/2022, 03:00:00
RIGL Rigel Pharmaceuticals 0.29 -0.4359 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst institutional investors who own 72% - Yahoo Eurosport UK 11/12/2022, 03:00:00
VBIV VBI Vaccines Inc. 0.29 -6.5421 VBI Vaccines Inc. (NASDAQ:VBIV) is a stock that investors should take a bite out of. - The Dwinnex 11/29/2022, 13:32:00
VBIV VBI Vaccines Inc. 0.29 -6.5421 Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022 - Yahoo Finance 11/29/2022, 10:58:00
VBIV VBI Vaccines Inc. 0.29 -6.5421 Gene therapy Hemgenix gains FDA clearance for hemophilia B - BioWorld Online 11/23/2022, 13:16:02
VBIV VBI Vaccines Inc. 0.29 -6.5421 Novavax Inc. stock falls Tuesday, underperforms market - MarketWatch 11/22/2022, 17:13:00
VBIV VBI Vaccines Inc. 0.29 -6.5421 VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting - VBI Vaccines 11/22/2022, 08:28:33
KDNY Chinook Therapeutics Inc 0.27 0.3467 Proteinuria Therapeutics Market Present Scenario and the Growth Prospects 2022 – 2028 GlaxoSmithKline plc - EIN News 11/29/2022, 07:09:00
KDNY Chinook Therapeutics Inc 0.27 0.3467 Primary Hyperoxaluria Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Primary Hyperoxaluria Pipeline Landscape - Digital Journal 11/25/2022, 12:02:57
KDNY Chinook Therapeutics Inc 0.27 0.3467 2022 Polycystic Kidney Disease Drugs in Development Report: Featuring Angion Biomedica, ATLAS Molecular Pharma, Bristol-Myers Squibb and Camurus Among Others - ResearchAndMarkets.com - WV News 11/25/2022, 06:48:39
KDNY Chinook Therapeutics Inc 0.27 0.3467 Chinook Therapeutics to Presen - GuruFocus.com 11/23/2022, 03:02:20
KDNY Chinook Therapeutics Inc 0.27 0.3467 Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes - EurekAlert 11/22/2022, 21:00:43
XNCR Xencor Inc 0.27 1.065 Canon doubles down on US presence with new $300M subsidiary - FierceBiotech 11/29/2022, 13:18:55
XNCR Xencor Inc 0.27 1.065 Boston Scientific snatches up gastro-focused Apollo Endosurgery for $615M - FierceBiotech 11/29/2022, 12:54:14
XNCR Xencor Inc 0.27 1.065 Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D - FierceBiotech 11/29/2022, 11:14:15
XNCR Xencor Inc 0.27 1.065 Philips unveils AI to improve diagnoses from imaging scans - FierceBiotech 11/29/2022, 10:50:33
XNCR Xencor Inc 0.27 1.065 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
BPMC Blueprint Medicines Corp 0.27 3.2501 Mackenzie Financial Corp Raises Position in Blueprint Medicines Co. (NASDAQ:BPMC) - ETF Daily News 11/29/2022, 04:44:21
BPMC Blueprint Medicines Corp 0.27 3.2501 Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM - Nasdaq 11/23/2022, 10:51:00
BPMC Blueprint Medicines Corp 0.27 3.2501 Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Hold" from Analysts - MarketBeat 11/22/2022, 01:15:09
BPMC Blueprint Medicines Corp 0.27 3.2501 Is Blueprint Medicines Corp (BPMC) Stock a Smart Investment Monday? - InvestorsObserver 11/21/2022, 13:12:27
BPMC Blueprint Medicines Corp 0.27 3.2501 Add Up The Parts: ESGV Could Be Worth $81 - Nasdaq 11/18/2022, 03:00:00
KYMR Kymera Therapeutics Inc 0.27 3.4394 Captor Therapeutics Reports Q3 2022 Results and Provides Business Update - GlobeNewswire 11/25/2022, 08:00:00
KYMR Kymera Therapeutics Inc 0.27 3.4394 Does Kymera Therapeutics Inc (KYMR) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver 11/23/2022, 15:37:17
KYMR Kymera Therapeutics Inc 0.27 3.4394 Kymera Therapeutics (KYMR) Shares Cross Below 200 DMA - Nasdaq 11/22/2022, 12:52:00
KYMR Kymera Therapeutics Inc 0.27 3.4394 Eczema Therapeutics Market Size to Grow by USD 4.36 Billion, 42% of the Market Growth to Originate from North America - Technavio - PR Newswire 11/22/2022, 11:00:00
KYMR Kymera Therapeutics Inc 0.27 3.4394 Merck Plans To 'Tuck In' Imago And Its Phase III-Ready Hematologic Candidate - Scrip 11/21/2022, 18:03:44
ARWR Arrowhead Pharmaceuticals Inc. 0.27 5.3571 Almirall signs on for European clinical trial project to collect data for patients - FierceBiotech 11/29/2022, 10:36:01
ARWR Arrowhead Pharmaceuticals Inc. 0.27 5.3571 Increasing dental disorders worldwide are expected to proliferate the Dental Implant Abutment Systems Market CAGR: ~7% UnivDatos Market Insights - Yahoo Finance 11/29/2022, 10:30:00
ARWR Arrowhead Pharmaceuticals Inc. 0.27 5.3571 Medicinal Chemistry for Drug Discovery Market to Observe Utmost Growth of USD 12,173.97 Million by 2029, Size, Share, Trends, Key Drivers, Development Trends and Industry Growth Outlook - Yahoo Finance 11/29/2022, 09:30:00
ARWR Arrowhead Pharmaceuticals Inc. 0.27 5.3571 Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal - FierceBiotech 11/29/2022, 08:24:27
ARWR Arrowhead Pharmaceuticals Inc. 0.27 5.3571 BigHat, cherry-picking opportunities amid stormy market, pens pact with Merck & Co. - FierceBiotech 11/29/2022, 08:05:06
TVTX Travere Therapeutics Inc 0.27 -0.1052 Proteinuria Therapeutics Market Present Scenario and the Growth Prospects 2022 – 2028 GlaxoSmithKline plc - EIN News 11/29/2022, 07:09:00
TVTX Travere Therapeutics Inc 0.27 -0.1052 JPMorgan Chase & Co. Grows Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Armenian Reporter 11/29/2022, 04:50:13
TVTX Travere Therapeutics Inc 0.27 -0.1052 Head to Head Survey: Minerva Neurosciences (NASDAQ:NERV) and Travere Therapeutics (NASDAQ:TVTX) - ETF Daily News 11/29/2022, 01:18:55
TVTX Travere Therapeutics Inc 0.27 -0.1052 Alport Syndrome Therapeutic Pipeline Analysis, 2022 Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Players - Digital Journal 11/28/2022, 21:33:35
TVTX Travere Therapeutics Inc 0.27 -0.1052 Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes - EurekAlert 11/22/2022, 21:00:43
TWST Twist Bioscience Corp 0.27 -1.5575 Transcript : Twist Bioscience Corporation - Special Call - Marketscreener.com 11/29/2022, 12:00:00
TWST Twist Bioscience Corp 0.27 -1.5575 Synthetic Biology Market is anticipated to expand at a CAGR of 19.2% from 2023 to 2032 insightSLIC - PharmiWeb.com 11/29/2022, 10:21:24
TWST Twist Bioscience Corp 0.27 -1.5575 Global NGS Kits Market to Reach $26.05 Billion by 2032 - Exclusive DeepTech M-A-P™ Analysis by BIS Research - Yahoo Finance 11/29/2022, 10:00:00
TWST Twist Bioscience Corp 0.27 -1.5575 North America DNA Digital Data Storage Market to Garner US$ 770.93 Mn by 2028 12.6% CAGR - Impact of COVID-1 - openPR 11/29/2022, 07:58:00
TWST Twist Bioscience Corp 0.27 -1.5575 Global Oligonucleotide Synthesis Global Market Report 2022: Featuring Agilent Technologies, CSBIO, Danaher, Kaneka & More - Yahoo Finance UK 11/29/2022, 04:53:00
HALO Halozyme Therapeutics Inc. 0.27 1.0271 Hyaluronidase Market Size to reach a revised size of US$ 2390.00 Mn by 2030 CAGR 12.0% - openPR 11/29/2022, 07:46:00
HALO Halozyme Therapeutics Inc. 0.27 1.0271 Halozyme Therapeutics, Inc. (HALO) Stock: How Does it Score on Fundamental Metrics? - InvestorsObserver 11/28/2022, 15:51:02
HALO Halozyme Therapeutics Inc. 0.27 1.0271 SPDR S&P Biotech ETF Experiences Big Outflow - Nasdaq 11/28/2022, 10:47:00
HALO Halozyme Therapeutics Inc. 0.27 1.0271 11 Best Diabetes Stocks To Buy Now - Yahoo Finance 11/27/2022, 17:27:45
HALO Halozyme Therapeutics Inc. 0.27 1.0271 Auto-Injectors Market Is Estimated to Grow At CAGR of 16.60%, 2022-2030 Latest Industry Coverage By Growth Plus Reports - GlobeNewswire 11/24/2022, 02:23:15
BRTX BioRestorative Therapies Inc 0.27 5.4924 Global Allogeneic Stem Cell Therapy Market is expected to grow at a CAGR of 9.85% by 2030 - Digital Journal 11/29/2022, 17:41:58
BRTX BioRestorative Therapies Inc 0.27 5.4924 BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022 - GlobeNewswire 11/29/2022, 11:20:00
BRTX BioRestorative Therapies Inc 0.27 5.4924 BioRestorative Therapies : BRTX Presentation November 2022 - Marketscreener.com 11/21/2022, 04:29:08
BRTX BioRestorative Therapies Inc 0.27 5.4924 BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 - GuruFocus.com 11/16/2022, 09:06:06
BRTX BioRestorative Therapies Inc 0.27 5.4924 Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027 - StreetInsider.com 11/15/2022, 09:35:59
CABA Cabaletta Bio Inc 0.27 8.7324 Will Cabaletta Bio Inc (CABA) Stay at the Top of the Healthcare Sector? - InvestorsObserver 11/29/2022, 13:29:24
CABA Cabaletta Bio Inc 0.27 8.7324 Where Does Cabaletta Bio Inc (CABA) Stock Fall in the Biotechnology Field After It Has Fallen -2.57% This Week? - InvestorsObserver 11/28/2022, 11:51:26
CABA Cabaletta Bio Inc 0.27 8.7324 Cabaletta Bio to Present at th - GuruFocus.com 11/22/2022, 08:08:08
CABA Cabaletta Bio Inc 0.27 8.7324 Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference - The Bakersfield Californian 11/22/2022, 08:02:59
CABA Cabaletta Bio Inc 0.27 8.7324 Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year? - Nasdaq 11/21/2022, 09:40:00
UBX Unity Biotechnology Inc 0.27 6.25 Mirum blames enrollment woes for halting phase 2 trial for pregnancy liver disorder - FierceBiotech 11/29/2022, 09:56:03
UBX Unity Biotechnology Inc 0.27 6.25 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
UBX Unity Biotechnology Inc 0.27 6.25 Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease - FierceBiotech 11/28/2022, 11:20:00
UBX Unity Biotechnology Inc 0.27 6.25 Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline - FierceBiotech 11/28/2022, 11:12:06
UBX Unity Biotechnology Inc 0.27 6.25 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:57:27
IVA Inventiva - ADR 0.27 5.7692 European ADRs Rise in Monday Trading - InvestorsObserver 11/07/2022, 12:04:03
IVA Inventiva - ADR 0.27 5.7692 FPIs Have Sold Off 29.7 Million Shares, Or 44% Of Their Holdings In Paytm. - Inventiva 11/05/2022, 03:00:00
IVA Inventiva - ADR 0.27 5.7692 European ADRs Move Higher in Friday Trading - Marketscreener.com 11/04/2022, 03:00:00
IVA Inventiva - ADR 0.27 5.7692 Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in Focus - Yahoo Finance 10/31/2022, 03:00:00
IVA Inventiva - ADR 0.27 5.7692 ADANI ENTERPRISE TO RAISE RS 1000CR VIA PUBLIC ISSUE OF DEBENTURES - Inventiva 10/21/2022, 03:00:00
PRTC PureTech Health Plc - ADR 0.27 5.3125 Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - Yahoo Finance 11/08/2022, 03:00:00
PRTC PureTech Health Plc - ADR 0.27 5.3125 PRTC Stock Forecast, Price & News (PureTech Health) - MarketBeat 11/17/2020, 11:07:24
NBY Novabay Pharmaceuticals Inc 0.27 0.4367 NovaBay Pharmaceuticals Announces the Launch of DERMAdoctor's TikTok Store in China and Expands Online Marketing in the U.S. and China - Business Wire 11/29/2022, 06:50:00
NBY Novabay Pharmaceuticals Inc 0.27 0.4367 Can NovaBay Pharmaceuticals Inc (NBY) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver 11/23/2022, 12:09:21
NBY Novabay Pharmaceuticals Inc 0.27 0.4367 North America and Europe Hypochlorous Acid Market is Anticipated to Expand at a CAGR of 4% from 2020 to 2030 - openPR 11/23/2022, 00:17:00
NBY Novabay Pharmaceuticals Inc 0.27 0.4367 Should You Sell NovaBay Pharmaceuticals Inc (NBY) in Biotechnology Industry? - InvestorsObserver 11/22/2022, 12:47:50
NBY Novabay Pharmaceuticals Inc 0.27 0.4367 NOVABAY PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/18/2022, 16:59:04
PSTV Plus Therapeutics Inc 0.27 -3.3613 Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration - Scrip 11/29/2022, 18:32:45
PSTV Plus Therapeutics Inc 0.27 -3.3613 Other news to note for Nov. 29, 2022 - BioWorld Online 11/29/2022, 17:41:50
PSTV Plus Therapeutics Inc 0.27 -3.3613 ALLOGENE THERAPEUTICS, INC. : Other Events (form 8-K) - Marketscreener.com 11/29/2022, 15:35:03
PSTV Plus Therapeutics Inc 0.27 -3.3613 Here's How to Find Cheap Stocks Under $10 to Buy for December - Yahoo Finance 11/29/2022, 12:57:05
PSTV Plus Therapeutics Inc 0.27 -3.3613 AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy - Scrip 11/29/2022, 12:37:43
MTEM Molecular Templates Inc 0.27 -2.521 Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI's 5th Annual HealthCONx Conference and Piper Sandler's 34th Annual Healthcare Conference - GlobeNewswire 11/23/2022, 16:30:00
MTEM Molecular Templates Inc 0.27 -2.521 What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates - Simply Wall St 11/16/2022, 03:00:00
MTEM Molecular Templates Inc 0.27 -2.521 7 Dallas-Area Companies Make Deloitte's 2022 Technology Fast 500 List - dallasinnovates.com 11/16/2022, 03:00:00
MTEM Molecular Templates Inc 0.27 -2.521 DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors Pipeline Landscape - Yahoo Finance 11/14/2022, 03:00:00
MTEM Molecular Templates Inc 0.27 -2.521 Barclays Adjusts Price Target on Molecular Templates to $1 From $4.50, Maintains Overweight Rating - Marketscreener.com 11/11/2022, 10:45:02
PIRS Pieris Pharmaceuticals Inc 0.27 -1.4554 Pieris Pharmaceuticals, Inc. (PIRS) Stock Price Today, Quote & News - Seeking Alpha 11/25/2022, 03:00:00
PIRS Pieris Pharmaceuticals Inc 0.27 -1.4554 Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference - AccessWire 11/23/2022, 08:07:24
PIRS Pieris Pharmaceuticals Inc 0.27 -1.4554 HER2+ Gastric Cancer Pipeline Analysis, 2022 Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies - Digital Journal 11/22/2022, 15:36:31
PIRS Pieris Pharmaceuticals Inc 0.27 -1.4554 Chronic Kidney Disease Drugs Market to Reach US$ 17832.5 Mn with a CAGR value of 4.5% by 2030 Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc. - Digital Journal 11/11/2022, 03:00:00
PIRS Pieris Pharmaceuticals Inc 0.27 -1.4554 Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference - AccessWire 11/09/2022, 03:00:00
SONN Sonnet BioTherapeutics Holdings Inc 0.27 -3.7624 Do Traders Think Sonnet BioTherapeutics Holdings, Inc. (SONN) Can Turn Around Friday? - InvestorsObserver 11/25/2022, 13:36:54
SONN Sonnet BioTherapeutics Holdings Inc 0.27 -3.7624 GMP Cytokines Market Size to Hit US$ 158.13 Million by 2027 - EIN News 11/22/2022, 01:53:00
SONN Sonnet BioTherapeutics Holdings Inc 0.27 -3.7624 15 Most Volatile Stocks to Buy Now - Yahoo Finance 11/21/2022, 03:00:00
SONN Sonnet BioTherapeutics Holdings Inc 0.27 -3.7624 Should You Hold Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Monday Morning? - InvestorsObserver 11/14/2022, 09:03:34
SONN Sonnet BioTherapeutics Holdings Inc 0.27 -3.7624 Premarket Mover: Sonnet BioTherapeutics Holdings, Inc. (SONN) Down 7.48% - InvestorsObserver 11/10/2022, 06:48:22
ALPN Alpine Immune Sciences Inc 0.27 -2.6772 Alpine Immune Sciences, Inc. Expected to Post FY2022 Earnings of ($1.58) Per Share (NASDAQ:ALPN) - MarketBeat 11/23/2022, 06:33:25
ALPN Alpine Immune Sciences Inc 0.27 -2.6772 Ancient oral microbiomes support gradual Neolithic dietary shifts towards agriculture - Nature.com 11/22/2022, 11:04:14
ALPN Alpine Immune Sciences Inc 0.27 -2.6772 Alpine Immune Sciences (NASDAQ:ALPN) Now Covered by SVB Leerink - MarketBeat 11/21/2022, 08:34:24
ALPN Alpine Immune Sciences Inc 0.27 -2.6772 Uveitis - Drug Pipeline Landscape, 2022 - openPR 11/17/2022, 03:00:00
ALPN Alpine Immune Sciences Inc 0.27 -2.6772 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Yahoo Finance 11/14/2022, 03:00:00
HTGM HTG Molecular Diagnostics Inc 0.27 4.5455 Cancer & Tumor Profiling and Pathways Market by Product Type (Immunoassays, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Microarrays, Mass Spectrometry, Others), Application (Research, Clinic - Skegness Siren 11/25/2022, 14:55:08
HTGM HTG Molecular Diagnostics Inc 0.27 4.5455 The Global miRNA Tools and Services Market size is expected to reach $939.8 million by 2028, rising at a market growth of 17.8% CAGR during the forecast period - Yahoo Finance 11/25/2022, 10:40:00
HTGM HTG Molecular Diagnostics Inc 0.27 4.5455 Immuno Oncology Assays Market Size, Status, and Growth Forecast 2022 to 2030 - openPR 11/23/2022, 04:49:00
HTGM HTG Molecular Diagnostics Inc 0.27 4.5455 Worldwide In Vitro Diagnostic Tests Market Report 2022 with Profiles of 200+ Companies - Financial Results, Product Launches, Company History and Strategic Plans - ResearchAndMarkets.com - Business Wire 11/22/2022, 07:10:00
HTGM HTG Molecular Diagnostics Inc 0.27 4.5455 HTG MOLECULAR DIAGNOSTICS, INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com 11/18/2022, 16:10:14
PHIO Phio Pharmaceuticals Corp 0.27 4.9738 Korea Warts Therapeutics Market Shares, Strategies, and Forecasts Analysis - openPR 11/15/2022, 03:00:00
PHIO Phio Pharmaceuticals Corp 0.27 4.9738 Incredible Growth Of Rna-Interference (Rnai) Market: Future Trend And Analysis Of Key Segments And Forecast 20 - openPR 11/14/2022, 03:00:00
PHIO Phio Pharmaceuticals Corp 0.27 4.9738 Appointments and advancements for Nov. 11, 2022 - BioWorld Online 11/11/2022, 03:00:00
PHIO Phio Pharmaceuticals Corp 0.27 4.9738 Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq 11/10/2022, 03:00:00
PHIO Phio Pharmaceuticals Corp 0.27 4.9738 Exclusive Report On Rna-Interference (Rnai) Market Size Will Witness Substantial Growth With In-Detailed Competitor Analysis Forecast To 2022-2030 - Digital Journal 11/08/2022, 03:00:00
KZR Kezar Life Sciences Inc 0.27 -2.4324 The Lupus Nephritis Market to Climb Swiftly at a Significant CAGR of 8.4% by 2032 DelveInsight - Digital Journal 11/29/2022, 03:59:44
KZR Kezar Life Sciences Inc 0.27 -2.4324 Pyruvate kinase (PK) deficiency Market is going to hit at a CAGR of 5.20% by 2028 - Digital Journal 11/22/2022, 05:56:36
KZR Kezar Life Sciences Inc 0.27 -2.4324 Polymyositis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mecha - openPR 11/22/2022, 04:52:00
KZR Kezar Life Sciences Inc 0.27 -2.4324 KZR-540 blocks PD-1 expression and inhibits tumor growth in vivo - BioWorld Online 11/18/2022, 09:00:00
KZR Kezar Life Sciences Inc 0.27 -2.4324 Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Hold (KZR) - Seeking Alpha 11/16/2022, 03:00:00
TRVN Trevena Inc 0.27 -2.3055 Trevena Regains Compliance wit - GuruFocus.com 11/29/2022, 07:03:10
TRVN Trevena Inc 0.27 -2.3055 Trevena Regains Compliance with Nasdaq Listing Requirements - Yahoo Finance 11/29/2022, 07:00:00
TRVN Trevena Inc 0.27 -2.3055 TREVENA INC : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/18/2022, 06:04:10
TRVN Trevena Inc 0.27 -2.3055 Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board - Yahoo Finance 11/17/2022, 07:00:00
TRVN Trevena Inc 0.27 -2.3055 Port Authority Focuses on 4th Ward Projects - businessjournaldaily.com 11/16/2022, 13:05:10
MRNA Moderna Inc 0.17 -1.5965 Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch 11/29/2022, 17:32:00
MRNA Moderna Inc 0.17 -1.5965 Moderna Inc. stock falls Tuesday, underperforms market - MarketWatch 11/29/2022, 16:32:00
MRNA Moderna Inc 0.17 -1.5965 What to Watch in the Day Ahead - Wednesday, November 30 - Kalkine Media 11/29/2022, 16:16:32
MRNA Moderna Inc 0.17 -1.5965 Moderna And Pfizer's MRNA Patent Cases Consolidated - Law360 11/29/2022, 14:56:00
MRNA Moderna Inc 0.17 -1.5965 Hustlers Fund to be launched on Wednesday - The Standard 11/29/2022, 12:03:20
EXAS Exact Sciences Corp. 0.15 -2.7711 Noteworthy ETF Outflows: ARKK, ZM, ROKU, EXAS - Nasdaq 11/29/2022, 10:56:00
EXAS Exact Sciences Corp. 0.15 -2.7711 Why This Biotech Firm is the Top Weight in ARKG - Nasdaq 11/28/2022, 12:42:00
EXAS Exact Sciences Corp. 0.15 -2.7711 Insights on the Liquid Biopsy Global Market to 2027 - Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic - Yahoo Finance 11/25/2022, 06:08:00
EXAS Exact Sciences Corp. 0.15 -2.7711 Breast Cancer Screening Market Expected to Reach at US$ 6209.25 Million by 2027 - EIN News 11/23/2022, 06:59:00
EXAS Exact Sciences Corp. 0.15 -2.7711 First Week of July 2023 Options Trading For EXACT Sciences - Nasdaq 11/21/2022, 10:58:00
BNTX BioNTech SE - ADR 0.15 1.4924 Should You Hold Immunic Inc (IMUX) in Biotechnology Industry? - InvestorsObserver 11/29/2022, 11:19:19
BNTX BioNTech SE - ADR 0.15 1.4924 How Will the Market React to BioNTech SE - ADR (BNTX) Stock Getting a Bullish Rating - InvestorsObserver 11/29/2022, 11:06:38
BNTX BioNTech SE - ADR 0.15 1.4924 Weekly Upgrades and Downgrades - InvestorPlace 11/28/2022, 13:46:22
BNTX BioNTech SE - ADR 0.15 1.4924 PFE: 1 High-Dividend Stock to Add to Your Portfolio if You Haven't Already - StockNews.com 11/28/2022, 13:40:30
BNTX BioNTech SE - ADR 0.15 1.4924 Should You Accumulate BioNTech SE - ADR (BNTX) Stock Monday? - InvestorsObserver 11/28/2022, 11:51:26
SRPT Sarepta Therapeutics Inc 0.1 -0.8719 Should You Add Sarepta Therapeutics Inc (SRPT) Stock to Your Portfolio Tuesday? - InvestorsObserver 11/29/2022, 12:48:23
SRPT Sarepta Therapeutics Inc 0.1 -0.8719 Astrazeneca paying up to $320M to acquire individualized TCR T-cell therapy developer Neogene - BioWorld Online 11/29/2022, 12:00:00
SRPT Sarepta Therapeutics Inc 0.1 -0.8719 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
SRPT Sarepta Therapeutics Inc 0.1 -0.8719 Notable Monday Option Activity: SRPT, WDAY, CSTM - Nasdaq 11/28/2022, 15:41:00
SRPT Sarepta Therapeutics Inc 0.1 -0.8719 CTLT stock spikes as Barclays says FDA cleared site violations (NYSE:CTLT) - Seeking Alpha 11/28/2022, 14:40:00
NGM Ngm Biopharmaceuticals Inc 0.03 3.071 Insider Buying: NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Director Purchases 35997 Shares of Stock - MarketBeat 11/23/2022, 18:43:25
NGM Ngm Biopharmaceuticals Inc 0.03 3.071 Metastatic Renal Cell Carcinoma Pipeline Landscape: 40+ Key Players DelveInsight - Digital Journal 11/14/2022, 21:19:16
NGM Ngm Biopharmaceuticals Inc 0.03 3.071 NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat 11/12/2022, 03:00:00
NGM Ngm Biopharmaceuticals Inc 0.03 3.071 Should You Buy NGM Biopharmaceuticals Inc (NGM) Stock on Tuesday? - InvestorsObserver 11/08/2022, 13:00:00
NGM Ngm Biopharmaceuticals Inc 0.03 3.071 Pancreatic Ductal Adenocarcinoma Pipeline Analysis: 80+ Companies are Working to Improve the Treatment Space DelveInsight - Digital Journal 11/08/2022, 03:00:00
LIXT Lixte Biotechnology Holdings Inc 0.03 9.8197 Gaucher Disease Treatment Market Will Have Its Revenue Spiking By 2028 Genzyme Corporation, Pfizer, Inc., Shire Human Genetics Therapies, Inc. - Digital Journal 11/29/2022, 05:54:46
LIXT Lixte Biotechnology Holdings Inc 0.03 9.8197 LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/10/2022, 16:16:44
LIXT Lixte Biotechnology Holdings Inc 0.03 9.8197 Uncleared Midterm Election Result Affects DIS, RBLX, LIXT Stock Price - The Coin Republic 11/10/2022, 03:00:00
LIXT Lixte Biotechnology Holdings Inc 0.03 9.8197 U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market Size will Grow Profitably in upcoming Estimation year 2028 Onconova Therapeutics, Inc., Acceleron Pharma, Inc., Cipla Limited, Sun Pharmaceutical Industries Limited. - Medgadget 10/18/2022, 03:00:00
LIXT Lixte Biotechnology Holdings Inc 0.03 9.8197 LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 - GlobeNewswire 10/13/2022, 03:00:00
APVO Aptevo Therapeutics Inc 0.03 7.2664 Envisagenics Announces Research Collaboration with Bristol Myers Squibb - Investing News Network 11/29/2022, 08:40:59
APVO Aptevo Therapeutics Inc 0.03 7.2664 AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022 - Investing News Network 11/28/2022, 16:50:00
APVO Aptevo Therapeutics Inc 0.03 7.2664 Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights - Yahoo Finance 11/10/2022, 03:00:00
APVO Aptevo Therapeutics Inc 0.03 7.2664 Health Canada Approves Camzyos for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Investing News Network 11/10/2022, 03:00:00
APVO Aptevo Therapeutics Inc 0.03 7.2664 Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics - Yahoo Finance 11/09/2022, 03:00:00
MTCR Metacrine Inc 0.03 -0.8605 Mirum blames enrollment woes for halting phase 2 trial for pregnancy liver disorder - FierceBiotech 11/29/2022, 09:56:03
MTCR Metacrine Inc 0.03 -0.8605 AstraZeneca inks $200M solid tumor TCR cell therapy buyout - FierceBiotech 11/29/2022, 07:01:16
MTCR Metacrine Inc 0.03 -0.8605 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
MTCR Metacrine Inc 0.03 -0.8605 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:57:27
MTCR Metacrine Inc 0.03 -0.8605 AstraZeneca beefs up COPD pipeline with $400M biobuck bet on C4X program - FierceBiotech 11/28/2022, 06:44:52
VCNX Vaccinex Inc 0.03 1.4552 13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance 11/29/2022, 17:43:35
VCNX Vaccinex Inc 0.03 1.4552 Cincor slammed over phase II miss with baxdrostat in uncontrolled high blood pressure - BioWorld Online 11/28/2022, 13:43:16
VCNX Vaccinex Inc 0.03 1.4552 Vaccinex Announces $3.8 Million Private Placement - GlobeNewswire 11/28/2022, 08:00:00
VCNX Vaccinex Inc 0.03 1.4552 Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update - Yahoo Finance 11/14/2022, 03:00:00
VCNX Vaccinex Inc 0.03 1.4552 Vaccinex earnings, Revenue beat in Q3 - Investing.com India 11/14/2022, 03:00:00
HGEN Humanigen Inc 0.03 -1.6835 Stock Performance And Forecast For Humanigen Inc. - Marketing Sentinel 11/29/2022, 08:30:08
HGEN Humanigen Inc 0.03 -1.6835 EQUITY ALERT: Rosen Law Firm E - GuruFocus.com 11/29/2022, 03:44:31
HGEN Humanigen Inc 0.03 -1.6835 Chagas Disease Treatment Market Anticipated to Generate a Revenue and Grow at a CAGR of 7.40% over the Estimated Timeframe - Digital Journal 11/17/2022, 05:38:51
HGEN Humanigen Inc 0.03 -1.6835 Humanigen, Inc. (HGEN) Stock Price Today, Quote & News - Seeking Alpha 11/17/2022, 03:00:00
HGEN Humanigen Inc 0.03 -1.6835 Humanigen Reports Third Quarter 2022 Financial Results - Yahoo Finance 11/14/2022, 03:00:00
ISR Isoray, Inc. 0.03 -0.1556 ISORAY, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com 11/29/2022, 16:29:03
ISR Isoray, Inc. 0.03 -0.1556 Radiotherapy Market 2022 Future Business Opportunities for Business Development Forecasts Up to 2030: Accuray Incorporated, Elekta, Isoray, CIVCO, Hitachi, Ltd., Mevion Medical Systems - Digital Journal 11/29/2022, 05:54:48
ISR Isoray, Inc. 0.03 -0.1556 Radiotherapy Market: Size, Share, Growth, Trends Current Analysis and Forecast (2022-2028) - EIN News 11/28/2022, 12:53:00
ISR Isoray, Inc. 0.03 -0.1556 Veterinary Stereotactic Radiosurgery System Market Report 2022 With Up To 70% Discount On Purchase Includes Demographic Trends, New Developments, Company Performance and Forecast 2029: PetCure Oncology (U.S.), Varian Medical Systems Inc. ( - Digital Journal 11/25/2022, 03:49:04
ISR Isoray, Inc. 0.03 -0.1556 The Global Radiation Oncology Devices Market to Climb Swiftly at a CAGR of 7.78% by 2027 DelveInsight - Medgadget 11/24/2022, 06:43:33
RAPT RAPT Therapeutics Inc 0.03 -6.3867 Atopic Dermatitis Treatment Global Market Report 2022: Focus on Novel Drugs with Novel Mechanisms Presents Opportunities - GlobeNewswire 11/28/2022, 05:18:50
RAPT RAPT Therapeutics Inc 0.03 -6.3867 With More than 150+ Molecules in Various Stages of Development, the Atopic Dermatitis Market to Witness Entry of New Drugs - Market Revenue to Cross USD 11 Billion by 2027 - Arizton - PR Newswire UK 11/22/2022, 12:00:00
RAPT RAPT Therapeutics Inc 0.03 -6.3867 Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick - Nasdaq 11/22/2022, 08:46:00
RAPT RAPT Therapeutics Inc 0.03 -6.3867 Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday - Ambarella (NASDAQ: - Benzinga 11/21/2022, 05:58:38
RAPT RAPT Therapeutics Inc 0.03 -6.3867 Financings for Nov. 18, 2022 - BioWorld Online 11/18/2022, 11:00:00
CYCC Cyclacel Pharmaceuticals Inc 0.03 -2.5434 Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology - Investing News Network 11/17/2022, 09:35:04
CYCC Cyclacel Pharmaceuticals Inc 0.03 -2.5434 After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi - FierceBiotech 11/10/2022, 10:14:27
CYCC Cyclacel Pharmaceuticals Inc 0.03 -2.5434 CYCLACEL PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com 11/10/2022, 03:00:00
CYCC Cyclacel Pharmaceuticals Inc 0.03 -2.5434 Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript - Seeking Alpha 11/09/2022, 03:00:00
CYCC Cyclacel Pharmaceuticals Inc 0.03 -2.5434 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Yahoo Finance 11/09/2022, 03:00:00
MBOT Microbot Medical Inc 0.03 5.5172 10 Best Robotic Stocks Under $10 - Yahoo Finance 11/21/2022, 15:04:40
MBOT Microbot Medical Inc 0.03 5.5172 Microbot Medical Announces New Webinar Series to Engage Stakeholders with Experts in the Healthcare Space - Yahoo Finance 11/15/2022, 03:00:00
MBOT Microbot Medical Inc 0.03 5.5172 Next-Generation Surgical Robotics Market By 2022: Size, Business Improvement, Offer and Valuable - The Knox Reports 11/06/2022, 02:00:00
MBOT Microbot Medical Inc 0.03 5.5172 Microbot Medical Receives Additional Patent Allowance in Israel for the LIBERTY® Robotic System - GlobeNewswire 11/03/2022, 03:00:00
MBOT Microbot Medical Inc 0.03 5.5172 Microbot Medical Adds the Head of the Interventional Radiology Unit of Europe's Largest Cancer Center, Dr. Thierry Jacques De Baère to its Scientific Advisory Board - GlobeNewswire 10/31/2022, 03:00:00
AWH Aspira Women`s Health Inc 0.03 9.375 Aspira Women's Health Announces the Commercial Launch of - GlobeNewswire 11/29/2022, 16:01:00
AWH Aspira Women`s Health Inc 0.03 9.375 Sienna Senior Living Inc. (LWSCF) Q3 2022 Earnings Call Transcript - Seeking Alpha 11/12/2022, 03:00:00
AWH Aspira Women`s Health Inc 0.03 9.375 Aspira: Q3 Earnings Snapshot - Macon Telegraph 11/11/2022, 03:00:00
AWH Aspira Women`s Health Inc 0.03 9.375 Aspira Women's Health Reports Third Quarter 2022 Financial - GlobeNewswire 11/10/2022, 03:00:00
AWH Aspira Women`s Health Inc 0.03 9.375 Aspira Women's Health Inc. (AWH) Q3 2022 Earnings Call Transcript - Seeking Alpha 11/10/2022, 03:00:00
ASLN ASLAN Pharmaceuticals Ltd - ADR 0.03 -10.3863 China COVID Deaths Rattle Asian Equities - Marketscreener.com 11/21/2022, 10:42:01
ASLN ASLAN Pharmaceuticals Ltd - ADR 0.03 -10.3863 Asian ADRs Rebound Modestly After Slow Start to Monday Trading - InvestorsObserver 11/14/2022, 10:59:02
ASLN ASLAN Pharmaceuticals Ltd - ADR 0.03 -10.3863 Asian ADRs Struggle to Claw Back into Positive Territory MarketScreener - Marketscreener.com 11/03/2022, 03:00:00
ASLN ASLAN Pharmaceuticals Ltd - ADR 0.03 -10.3863 ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis - Nasdaq 01/21/2022, 03:00:00
OCUP Ocuphire Pharma Inc 0.03 5.3872 Glaucoma Pipeline Assessment 70+ Companies & 70+ Drugs DelveInsight - Digital Journal 11/29/2022, 16:16:47
OCUP Ocuphire Pharma Inc 0.03 5.3872 Ocular Hypertension Therapeutic Pipeline Analysis, 2022 In-depth Insights into the Latest FDA, EMA, and PMDA - openPR 11/28/2022, 04:31:00
OCUP Ocuphire Pharma Inc 0.03 5.3872 2022-11-21 NDAQ:OCUP Press Release Ocuphire Pharma Inc. - Stockhouse 11/21/2022, 08:06:39
OCUP Ocuphire Pharma Inc 0.03 5.3872 Ocuphire to Present at Five Up - GuruFocus.com 11/21/2022, 08:02:08
OCUP Ocuphire Pharma Inc 0.03 5.3872 Other news to note for Nov. 15, 2022 - BioWorld Online 11/15/2022, 03:00:00
MGTA Magenta Therapeutics Inc 0.03 -8.7719 Sarepta-partnered Hansa touts new phase 2 data of one-trick pony immunological treatment - FierceBiotech 11/28/2022, 15:43:26
MGTA Magenta Therapeutics Inc 0.03 -8.7719 Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease - FierceBiotech 11/28/2022, 11:20:00
MGTA Magenta Therapeutics Inc 0.03 -8.7719 Sanofi-backed Escient scores $120M series C for neuro-inflammatory pipeline - FierceBiotech 11/28/2022, 11:12:06
MGTA Magenta Therapeutics Inc 0.03 -8.7719 Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal - FierceBiotech 11/28/2022, 10:57:27
MGTA Magenta Therapeutics Inc 0.03 -8.7719 Slope's Hope Meely on the importance of a fully enabled clinical supply platform - FierceBiotech 11/28/2022, 08:00:00
SEEL Seelos Therapeutics Inc 0.03 -4.1611 COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference - Investing News Network 11/28/2022, 16:28:22
SEEL Seelos Therapeutics Inc 0.03 -4.1611 Albert Labs Announces Private Placement - Investing News Network 11/25/2022, 09:37:23
SEEL Seelos Therapeutics Inc 0.03 -4.1611 SEELOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com 11/23/2022, 16:06:08
SEEL Seelos Therapeutics Inc 0.03 -4.1611 Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022 - PR Newswire 11/23/2022, 08:00:00
SEEL Seelos Therapeutics Inc 0.03 -4.1611 Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction - Investing News Network 11/21/2022, 09:35:32